Events and Presentations

Recent Events

Jan 3, 2017
Biotech Showcase Investor Conference
KPI Therapeutics to Give Corporate Update at Biotech Showcase Investor Conference during JP Morgan Week
Learn More »
Nov 16, 2016
2nd Inflammatory Skin Disease Summit
KPI-150, a potent inhibitor of Kv1.3 potassium channels demonstrates preclinical proof of concept efficacy against atopic dermatitis when applied topically
Learn More »
Jun 24, 2016
Federation of Clinical Immunology Societies
Inhibition of the potassium channel Kv1.3 by dalazatide, a potential immunotherapy strategy for systemic lupus erythematosus
Learn More »
Jun 8, 2016
European League Against Rheumatism (EULAR) 2016
Dalazatide, a novel inhibitor of the Kv1.3 channel on activated effector memory T cells, has immunotherapy potential against systemic lupus erythematosus
Learn More »
May 11, 2016
75th Society for Investigative Dermatology
Dalazatide (ShK-186), a first-in-class peptide inhibitor of Kv1.3 potassium channels, demonstrates safety, tolerability, and proof of concept of efficacy in patients with active plaque psoriasis
Learn More »
Mar 21, 2016
8th Ocular Diseases Drug Discovery
Novel peptide inhibitors of the Kv1.3 potassium channel demonstrate efficacy in an anterior uveitis model
Learn More »
Feb 29, 2016
8th Annual Neuromyelitis Optica Roundtable
Dalazatide as a therapeutic candidate in NMO/SD
Learn More »
Nov 9, 2015
American College of Rheumatology’s (ACR) Annual Meeting
Dalazatide (ShK-186), a first-in-class blocker of Kv1.3 potassium channel on effector memory T cells: Safety, tolerability and proof of concept of immunomodulation in patients with active plaque psoriasis
Learn More »
Nov 9, 2015
American College of Rheumatology’s (ACR) Annual Meeting
Dalazatide (ShK-186), a Kv1.3 inhibitor that targets effector memory T cells: Ex vivo studies in pediatric systemic lupus erythematosus
Learn More »
Nov 9, 2015
American College of Rheumatology’s (ACR) Annual Meeting
Dalazatide modulates CD4+ effector memory T cell activity of patients with Granulomatosis with polyangiitis
Learn More »
Sep 23, 2015
Basel Life Science Week
Dalazatide, a first-in-class blocker of the Kv1.3 potassium channel on effector memory T cells: safety, tolerability and proof of concept immunomodulation in patients with active plaque psoriasis
Learn More »
Aug 10, 2015
12th World Congress on Inflammation
Dalazatide (ShK-186), a Kv1.3 potassium channel blocker, significantly reduces inflammatory cell infiltrates and disease in an experimental autoimmune anterior uveitis model
Learn More »
Aug 10, 2015
12th World Congress on Inflammation
Results from ShK186-03, a 28-day phase 1b trial of dalazatide (ShK-186), a Kv1.3 potassium channel blocker, in patients with active plaque psoriasis.
Learn More »
Jul 7, 2015
13th Annual Ion Channel Retreat
Dalazatide, first-in-class Kv1.3 blocker, an immunomodulator’s journey from the sea to the clinic
Learn More »
Jul 7, 2015
13th Annual Ion Channel Retreat
Kv1.3 channel blocker ShK-186: a potential novel therapeutic for ANCA vasculitis and lupus nephritis
Learn More »

Upcoming Events

Apr 26, 2017
Society for Investigative Dermatology 76th Annual Meeting
KPI Therapeutics Will Present New, Positive Data on KPI-150 as a Potential New Therapy for Atopic Dermatitis at Upcoming Skin Disease Conference
Learn More »